0 Comment
The drug Tolvaptan has been given the green light in the UK as the first-ever treatment for autosomal dominant polycystic kidney disease. A few months earlier it also received approval in Europe. It's the first ever treatment for autosomal dominant polycystic kidney disease (ADPKD), an incurable genetic condition that can cause heart attacks, stroke and kidney failure. The disease hits 60,000

Post a Comment

 
Top